29th May 2007 16:12
The MedicX Fund Limited29 May 2007 For Immediate Release 29 May 2007 NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, NEW ZEALAND, IRELAND OR SOUTH AFRICA ADVERTISEMENT This document does not constitute or form part of any offer or invitation tosell or issue, or any solicitation of any offer to subscribe for, any C Sharesor any other securities, nor shall it (or any part of it), or the fact of itsdistribution, form the basis of, or be relied on in connection with, anycontract relating thereto. This document is an advertisement and not aprospectus, and investors should not subscribe for any C Shares referred to inthis document except on the basis of the information in the Prospectus. Copiesof the Prospectus are available from the Company's registered office. Prospective investors should only rely on the information contained in theProspectus. No person has been authorised to give any information or make anyrepresentation other than those contained in the Prospectus. If given or made,such information must not be relied upon as having been authorised by theCompany or Panmure Gordon (UK) Limited ("Panmure Gordon"). MedicX Fund Limited ("MedicX Fund", "the Fund" or "the Company") Result of Placing and Offer for Subscription for C Shares and EGM held today Further to the announcement on 2 May 2007 of a proposed Placing and Offer tosubscribe for C Shares in MedicX Fund Limited (MXF), the Official Listedspecialist investor in modern purpose built primary healthcare properties, theDirectors of the Company today announce that the Company has successfully raised£22.2 million (before expenses), by way of a Placing and Offer for Subscriptionof C Shares at 100p per share. The proceeds from the Issue will be used to fundthe Company's investment programme in primary healthcare properties. At the Extraordinary General Meeting held today, the special resolutionapproving the Issue was passed by the Company's shareholders. The Placing andOffer for Subscription remain conditional upon Admission to the Official List ofthe London Stock Exchange, which is expected to take place at 8.00am on 4 June2007 with dealings in the C Shares expected to commence shortly thereafter. Theticker symbol for the C Shares will be MXFC. Panmure Gordon is acting as sponsorand broker in respect of the Placing and Offer for Subscription. All terms used in this announcement are defined as set out in the Prospectusdated 2 May 2007. - ends - For further information please contact: MedicX FundAlison Simpson Tel: 01481 723 450 MedicX GroupKeith Maddin Tel: 01483 869 500 Mike Adams Buchanan CommunicationsCharles Ryland Tel: 020 7466 5000 Lisa Baderoon Mary-Jane Johnson Panmure Gordon (UK) LimitedEdward Farmer Tel: 020 7459 3600 Stuart Gledhill Callum Stewart The contents of this announcement have been approved for the purposes of section21 of the Financial Services and Markets Act 2000 as amended ("FSMA") by PanmureGordon (UK) Limited ("Panmure Gordon") of Moorgate Hall, 155 Moorgate, London,EC2M 6XB. Panmure Gordon is authorised and regulated in the United Kingdom bythe Financial Services Authority in respect of regulated activities and isacting as sponsor and broker in respect of the Placing and Offer forSubscription. Panmure Gordon is acting solely for MedicX Fund Limited inconnection with the Placing and Offer for Subscription and will not beresponsible to anyone other than MedicX Fund Limited for providing theprotections afforded to clients of Panmure Gordon nor for providing advice inrelation to the Placing and Offer for Subscription. This announcement is not for release, publication or distribution, in whole orin part, in or into the United States, Australia, Canada, Japan, South Africa,New Zealand, the Republic of Ireland or Australia (the "Prohibited Territories"). The Shares have not been and will not be registered under the US SecuritiesAct of 1933 (as amended), the United States Investment Company Act of 1940 (asamended) or under the applicable securities laws of the other ProhibitedTerritories and, unless an exemption under such laws is available, may not beoffered for sale or subscription or sold or subscribed directly or indirectlywithin the USA or the other Prohibited Territories or for the account or benefitof any national, resident or citizen of the USA or the other ProhibitedTerritories. Copies of the Prospectus are available during normal business hours on anyweekday (Saturdays, Sundays and public holidays excepted) at the offices ofPanmure Gordon, Moorgate Hall, 155 Moorgate, London EC2M 6XB until Admission andfor the 14 days following Admission. The Prospectus is also available at thedocument viewing facility of the UKLA at the UKLA Document Viewing Facility,Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E145HS. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Medicx Fund